A Phase I, Randomized, Single-Blind, Placebo-Controlled Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Food Effect Following Single Oral Doses of the Focal Adhesion Kinase Inhibitor, GSK2256098, in Healthy Subjects.

Trial Profile

A Phase I, Randomized, Single-Blind, Placebo-Controlled Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Food Effect Following Single Oral Doses of the Focal Adhesion Kinase Inhibitor, GSK2256098, in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs GSK 2256098 (Primary)
  • Indications Cancer
  • Focus Adverse reactions; Biomarker; Pharmacokinetics
  • Acronyms FTIH
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 19 May 2010 Trial acronym FTIH identified as reported by ClinicalTrials.gov.
    • 19 May 2010 Actual patient number amended from 24 to 38 as reported by ClinicalTrials.gov.
    • 23 Mar 2010 Actual patient number (24) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top